Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221074681. doi: 10.1177/10760296221074681.
To investigate the efficacy and safety of the antithrombotic therapy using the oral anticoagulant rivaroxaban and clopidogrel in Chinese patients with acute coronary syndrome complicated with atrial fibrillation after percutaneous coronary intervention.
A total of 100 patients were selected. Patients were randomly divided into two groups: the treatment group (rivaroxaban group) received a therapy of rivaroxaban and clopidogrel. The control group (warfarin group) receivied a combined treatment of warfarin, clopidogrel, and aspirin. The primary outcome endpoint was evaluated based on the adverse cardiac and cerebrovascular events within 12 months.
A total of 8 (8.00%) main adverse cardiac and cerebrovascular events occurred during the 12 months of follow-up, including 5 (9.80%) in the warfarin group and 3 (6.10%) in the rivaroxaban group. The risk of having main adverse cardiac and cerebrovascular events in the two groups was comparable (P = 0.479). A total of 9 patients (9.00%) were found to have bleeding events, among which 8 patients (15.7%) were in the warfarin group, whereas only 1 patient (2.00%) was in the rivaroxaban group. Therefore, the risk of bleeding in the warfarin group was significantly higher than that in the rivaroxaban group (P = 0.047).
In Chinese patients with acute coronary syndrome complicated with atrial fibrillation, the efficacy of the dual therapy of oral anticoagulant rivaroxaban plus clopidogrel after percutaneous coronary intervention was similar to that of the traditional triple therapy combined with warfarin, aspirin and clopidogrel, but it has a better safety property, which has potential to widely apply to antithrombotic therapy after PCI.
研究口服抗凝剂利伐沙班联合氯吡格雷在经皮冠状动脉介入治疗后合并心房颤动的急性冠状动脉综合征中国患者中的疗效和安全性。
共选择 100 例患者。患者随机分为两组：治疗组（利伐沙班组）给予利伐沙班联合氯吡格雷治疗。对照组（华法林组）给予华法林、氯吡格雷和阿司匹林联合治疗。主要终点是评估 12 个月内的不良心脑血管事件。
在 12 个月的随访中，共有 8 例（8.00%）主要不良心脑血管事件发生，华法林组 5 例（9.80%），利伐沙班组 3 例（6.10%）。两组发生主要不良心脑血管事件的风险相当（P=0.479）。共有 9 例（9.00%）发生出血事件，其中华法林组 8 例（15.7%），利伐沙班组 1 例（2.00%）。因此，华法林组的出血风险明显高于利伐沙班组（P=0.047）。
在中国急性冠状动脉综合征合并心房颤动患者中，口服抗凝剂利伐沙班加氯吡格雷双联治疗经皮冠状动脉介入治疗后的疗效与传统三联治疗（华法林、阿司匹林和氯吡格雷）相似，但安全性更好，具有广泛应用于 PCI 后抗栓治疗的潜力。
